Статья
Плейотропная активность антигипертензивных препаратов в атеротромбогенезе. Небиволол: расширение возможностей и снижение ограничений
В обзоре обсуждаются вопросы применения антигипертензивных препаратов (АГП) с позиции последних европейских рекомендаций. Oсобое внимание уделяется положению β-адреноблокаторов (β-АБ) в лечении пациентов с артериальной гипертонией (АГ). Oбсуждаются существующие различия в фармакологических свойствах и клинических эффектов β-АБ разных поколений. Oбосновывается важность классификации пациентов с АГ по величине общего сердечно-сосудистого риска. На примере небиволола рассматривается важность дополнительных (плейотропных) эффектов АГП в противодействии атеротромбогенезу.
1. Mancia G, Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the of the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 26: 1105–87.
2. Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. J Hypertens 2001; 37: 250–4.
3. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.
4. Opie LH, Schall R. Old antihypertensives and diabetes. J Hypertens 2004; 22: 1453–8.
5. Carlberg B, Samuelsson O, Lindholm LH, Atenolol in hypertension: is it a wise chouse? Lancet 2004; 364: 1684–9.
6. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.
7. Dahlцf B, Sever P, Poulter N, et al. Prevention of coronary and store events with antihypertension regimen of amlodip- ine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Ango-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTT- LLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
8. New BHS-NICE guidelines (June 2006). Prescription guidelines in cardiology. Editions Frison-Roche 2006.
9. Zanchetti A. Clinical pharmacodymamics of nebivolol: new evidence of nitric oxide-mediated vasodilatating activity and peculiar hemodynamic properties in hypertensive patients. Blood Pressure 2004; 13(Suppl 1): 17–32.
10. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; XVII (5): 335–71.
11. Kamp O, Sieswerda GT, Visser CA. Favorable effects on systolic and diastolic left ventricular function of nebivolol in comparison to atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344–8.
12. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of the patients with diastolic heart failure and arterial hypertension. A prospective randomized comparison of the long0term effects of atenolol versus nebivolol. Eur J Heart Fail 2003; 5: 621–7.
13. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25.
14. Edes I, Gasior Z, Wita K. Effect of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005; 7: 631–9.
15. Taddei S, Virdis A, Chiadoni L, Salvetti A The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21: 22–9.
16. Lusher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20(Suppl II): II-3–10.
17. Gardiner SM, Compton AM, Bennet T, et al. Control of regional blood flow by endothelium-derived nitric oxide. J Hypertens 1990; 15: 486–92.
18. Задионченко В.С., Адашева Т.В., Сандамирская А.П., Суворова С.С. Дисфункция эндотелия, артериальная гипертония: терапевтические возможности. Кардиоваск тер про- фил 2003; 2: 79–90.
19. Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 6: 934–40.
20. Schдchinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899–906.
21. Maffei H, Vecchione C, Aretini A, et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 2006; 19: 579–86.
22. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta-3- adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta- blocker nebivolol. Circulation 2005; 112: 1198–205.
23. Garban HJ, Buga GM, Ignarro LJ. Estrogen-receptor mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 2004; 43: 638–44.
24. Rosei EA, Rizzoni D. Metabolic profile of nebivolol, a β-adrenoceptor antagonist with unique characteristics. Drug 2007; 67: 1097–107.
25. Gosgnach W, Boixel C, Nevo N, et al. Nebivolol induce calcium- independent signaling in endothelial cells by a possible β-adrenergic pathway. J Cardiovasc Pharmacol 2001; 38: 191–9.
26. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third- generation β-blocker stimulation nitric oxide release from endothelial cells through ATP efflux. Circulation 2003; 107: 2747–52.
27. Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertension patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8: 127–34.
28. Cirillo P, Golino P, Calabro P, et al. C-rtactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005; 68: 47–55.
29. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectine and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591–6.
30. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implica- tions for impaired vasomotion. Am J Cardiol 1995; 75: 75B-81.
31. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4- keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. JACC 2003; 42: 1838–44.
32. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decrease systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000; 50: 377–9.
33. Fratta Passini A, Garbin U, Nava MC, et al. Nebivolol decrease oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589–96.
34. Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007; 19: 129–36.
35. Pesant Y, Marc-Aurele J, Bielman P, et al. Metabolic and antihypertension effects of nebivolol and atenolol in normometabolic patients with mild-moderate hypertension. Am J Therap 1999; 6: 137–47.
36. Gryglewski RJ, Uracz W, Marcinkiewicz E, et al. Role of endothelial nitric oxide in pleiotropic action of cardiovascular drug: nebivolol. In Gryglewski RJ and Minuz P, editors. Nitric oxide: basis research and clinical applications. Amsterdam: IOS Press, 2001: 57–69.
37. Falciani M, Rinaldi B, D`Agostino B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001; 38: 922–9.
38. Rabkin SW. Mechanisms of action of abrenergin receptor blockers on lipid during antihypertensive drug treatment. J Clin Pharmacol 1993; 33: 286–91.
39. Von Fallois J, Faulhaber HD. Nebivolol, a beta-blocker of 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study. Schweiz Rundsch Med Prax 2001; 90: 435–41.
40. Christlieb R, Mmaki P. The effect beta-blocker therapy on glucose, lipid metabolism. Primary Cardiol 1980; 1(Suppl): 47–54.
41. Маколкин В.И., Ахмедова О.О., Бувальцев В.И. и др. Клинические и метаболические эффекты кардиоселективных β-блокаторов небиволола и метопролола у больных артериальной гипертонией и ишемической болезнью сердца в сочетании с сахарным диабетом 2-го типа. Кардиология 2003; 2: 40–3.
42. DeFronzo RA, Ferrannini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia. Diabetes Care 1991; 14: 173–7.
43. Swisloski ALM. Impaired insulin clearance in essential hypertension. J Hum Hypertens 1994; 8: 185–90.
44. Rocchini AP, Moorehead C, Katch V, et al. Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. J Hypertension 1992; 19: 615–20.
45. Naruse M, Tanabe A, Takagi S, et al. Insulin resistance and vascular function. Nippon Rinsho 2000; 58: 344–7.
46. Shepherd PR, Kahn BB. Glucose transporter and insulin action. Implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341: 248–57.
47. Kumada M, Kihara S, Sumitsuji S, et al. Osaka CAD Study Group. Association of hypoadiponectinemia with coronary heart diseases in men. Arterioscler Tromb Vasc Biol 2003; 23: 85–9.
48. Евдокимова А.Г., Радзевич А.Э., Терещенко О.И., Коваленко Е.В. Оценка клинической эффективности включения небиволола и метопролола в комплексную терапию больных ишемической болезнью сердца с хронической сердечной недостаточностью II-III функциональных классов. Кардиоваск тер профил 2005; 4: 52–9.